4-<<3,4-(methylenedioxy)benzyl>amino>-6-(methylthio)quinazoline | 150450-45-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-<<3,4-(methylenedioxy)benzyl>amino>-6-(methylthio)quinazoline
• 英文别名: 4-(3,4-methylenedioxybenzyl)amino-6-methylthioquinazoline；Benzo[1,3]dioxol-5-ylmethyl-(6-methylsulfanyl-quinazolin-4-yl)-amine；N-(1,3-benzodioxol-5-ylmethyl)-6-methylsulfanylquinazolin-4-amine
• CAS: 150450-45-6
• 化学式: C₁₇H₁₅N₃O₂S
• 分子量: 325.391
• InChiKey: ZSNLDKXJGHWPBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  81.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-<<3,4-(methylenedioxy)benzyl>amino>-6-(methylthio)quinazoline 在 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 2.0h， 以80%的产率得到4-<<3,4-(methylenedioxy)benzyl>amino>-6-(methylsulfinyl)quinazoline
  参考文献：
  名称：

  Cyclic GMP Phosphodiesterase Inhibitors. 2. Requirement of 6-Substitution of Quinazoline Derivatives for Potent and Selective Inhibitory Activity

  摘要：

  We synthesized various 4-[[3,4-(methylenedioxy)benzyl]amino]quinazolines substituted at the 5-to 8-positions and evaluated their inhibitory activities toward cyclic GMP phosphodiesterase (cGMP-PDE) from porcine aorta, Monosubstitution at the 6-position was essential for the inhibitory activity, and the preferred substituents were compact and hydrophobic: methoxy (3b, IC50 = 0.23 mu M), methyl (3c, 0.10 mu M), chloro (3d, 0.019 mu M), thiomethyl (3f, 0.031 mu M), and cyano (3p, 0.090 mu M) groups. Compounds 3b-d,f,p lacked inhibitory activity toward other PDE isozymes (all IC50 values > 100 mu M), and their relaxing activities in porcine coronary arteries were well correlated with the inhibitory activities toward cGMP-PDE (r = 0.88, p < 0.05). One of these compounds, 3b, elevated the intracellular cGMP level in isolated porcine coronary arteries without causing any change in the cAMP level. We consider that this series of compounds dilates coronary arteries via potent and specific inhibition of cGMP-PDE,

  DOI：

  10.1021/jm00039a024
• 作为产物：
  描述：

  6-(methylthio)quinazolin-4(3H)-one 在 sodium carbonate 、 三氯氧磷 作用下， 以 异丙醇 为溶剂， 反应 3.0h， 生成 4-<<3,4-(methylenedioxy)benzyl>amino>-6-(methylthio)quinazoline
  参考文献：
  名称：

  Cyclic GMP Phosphodiesterase Inhibitors. 2. Requirement of 6-Substitution of Quinazoline Derivatives for Potent and Selective Inhibitory Activity

  摘要：

  We synthesized various 4-[[3,4-(methylenedioxy)benzyl]amino]quinazolines substituted at the 5-to 8-positions and evaluated their inhibitory activities toward cyclic GMP phosphodiesterase (cGMP-PDE) from porcine aorta, Monosubstitution at the 6-position was essential for the inhibitory activity, and the preferred substituents were compact and hydrophobic: methoxy (3b, IC50 = 0.23 mu M), methyl (3c, 0.10 mu M), chloro (3d, 0.019 mu M), thiomethyl (3f, 0.031 mu M), and cyano (3p, 0.090 mu M) groups. Compounds 3b-d,f,p lacked inhibitory activity toward other PDE isozymes (all IC50 values > 100 mu M), and their relaxing activities in porcine coronary arteries were well correlated with the inhibitory activities toward cGMP-PDE (r = 0.88, p < 0.05). One of these compounds, 3b, elevated the intracellular cGMP level in isolated porcine coronary arteries without causing any change in the cAMP level. We consider that this series of compounds dilates coronary arteries via potent and specific inhibition of cGMP-PDE,

  DOI：

  10.1021/jm00039a024

文献信息

• Anti-ischemic 2,4-diaminoquinazolines
  申请人：Eisai Co., Ltd.

  公开号：US05576322A1

  公开（公告）日：1996-11-19

  The invention is directed to certain 2,4-diaminoquinazoline compounds, their pharmaceutically acceptable salts, the pharmaceutical compositions comprising those compounds and their therapeutic methods of use. The compounds possess anti-ischemic activity.

  这项发明涉及特定的2,4-二氨基喹唑啉化合物，它们的药用盐，包含这些化合物的药物组合物以及它们的治疗用途方法。这些化合物具有抗缺血活性。
• Benzimidazoles for ischemic heart conditions
  申请人：Eisai Co., Ltd.

  公开号：US05693652A1

  公开（公告）日：1997-12-02

  The present invention provides a nitrogenous heterocyclic compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof which is useful for various ischemic heart diseases and the like: ##STR1## \x9bin formula (1), ring A represents a benzene ring, a pyridine ring or a cyclohexane ring: ring B represents a pyridine ring, a pyrimidine ring or an imidazole ring, R.sup.1, R.sup.2, R.sup.3 R.sup.4, R.sup.5 and R.sup.6 are described herein.

  本发明提供了一种由下列通式（1）表示的含氮杂环化合物或其药学上可接受的盐，其对于各种缺血性心脏疾病等具有有用的作用：##STR1## 在式（1）中，环A表示苯环、吡啶环或环己烷环；环B表示吡啶环、嘧啶环或咪唑环；R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5和R.sup.6在此已描述。
• Quinazoline derivatives
  申请人：Eisai Co., Ltd.

  公开号：US05801180A1

  公开（公告）日：1998-09-01

  The present invention provides a nitrogenous heterocyclic compound represented by the following general formula (1) or a pharmacologically acceptable salt thereof which is useful for various ischemic heart diseases and the like: ##STR1## \x9bin formula (1), ring A represents a benzene ring, a pyridine ring or a cyclohexane ring; ring B represents a pyridine ring, a pyrimidine ring or an imidazole ring, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent each a hydrogen atom, a halogen atom or a group such as a lower alkoxy group; R.sup.5 represents a group represented by the formula --NR.sup.11 R.sup.12 (wherein R.sup.11 and R.sup.12 represent each a hydrogen atom or a group such as a lower alkyl group) or the like; and R.sup.6 represents a group represented by the formula ##STR2## (wherein R.sup.19 represents a hydrogen atom, a lower alkyl group or the like; R.sup.20, R.sup.21 and R.sup.22 represent each a hydrogen atom, a halogen atom, a hydroxyl group or the like; and r represents 0 or an integer of 1 to 8)!.

  本发明提供了一种由以下通式（1）表示的含氮杂环化合物或其药学上可接受的盐，该化合物对各种缺血性心脏疾病等具有有用作用： ##STR1## 在公式（1）中，环A代表苯环、吡啶环或环己烷环；环B代表吡啶环、嘧啶环或咪唑环，R.sup.1、R.sup.2、R.sup.3和R.sup.4分别代表氢原子、卤原子或类似的低烷氧基团；R.sup.5代表由公式--NR.sup.11 R.sup.12（其中R.sup.11和R.sup.12分别代表氢原子或类似的低烷基团）或类似团代表的基团；R.sup.6代表由公式##STR2##（其中R.sup.19代表氢原子、低烷基团或类似物；R.sup.20、R.sup.21和R.sup.22分别代表氢原子、卤原子、羟基或类似物；r代表0或1到8的整数）的基团。
• NITROGENOUS HETEROCYCLIC COMPOUND
  申请人：Eisai Co., Ltd.

  公开号：EP0607439A1

  公开（公告）日：1994-07-27

  A nitrogenous heterocyclic compound represented by general formula (I) or a pharmacologically acceptable salt thereof, efficacious in treating various ischemic cardiac diseases, wherein ring A represents a benzene, pyridine or cyclohexane ring; ring B represents a pyridine, pyrimidine or imidazole ring; R¹, R², R³ and R⁴ represent each hydrogen, halogen, lower alkoxy, etc.; R⁵ represents -NR¹¹R¹² (wherein R¹¹ and R¹² represent each hydrogen, lower alkyl, etc.), etc.; and R⁶ represents (a) (wherein R¹⁹ represents hydrogen, lower alkyl, etc.; R²⁰, R²¹ and R²² represent each hydrogen, halogen, hydroxy, etc.; and r represents an integer of 0.1 to 8), etc.

  一种由通式(I)代表的含氮杂环化合物或其药理学上可接受的盐，可有效治疗各种缺血性心脏病，其中环 A 代表苯环、吡啶环或环己烷环；环 B 代表吡啶环、嘧啶环或咪唑环；R¹、R²、R³ 和 R⁴ 分别代表氢、卤素、低级烷氧基等；R⁵ 代表 -NR¹R¹² (其中 R¹¹ 和 R¹² 分别代表氢、低级烷基等)；以及 R⁶ 代表 -NR¹R¹² (其中 R¹¹ 和 R¹² 分别代表氢、低级烷基等)。R⁵代表-NR¹R¹²（其中 R¹¹ 和 R¹² 分别代表氢、低级烷基等）等；以及 R⁶ 代表（a）（其中 R¹⁹ 代表氢、低级烷基等；R²⁰、R²¹ 和 R²² 分别代表氢、卤素、羟基等；以及 r 代表 0.1 至 8 的整数）等。
• US6046206
  申请人：——

  公开号：——

  公开（公告）日：——